Ohio Valley Node

T. John Winhusen, PhD [email]
Principal Investigator
University of Cincinnati
Addiction Sciences Division
3131 Harvey Ave.
Cincinnati, OH 45219

Related Resources

Node web site
Node Facebook page
NIDA web site

The Ohio Valley Node joined the Clinical Trials Network in September 2000. As of September 2010, the OVN consists of 23 community-based treatment programs in 15 states in the Midwest region of the United States: West Virginia, Ohio, Kentucky, Tennessee, Michigan, Wisconsin, Illinois, Indiana, Missouri, Minnesota, Kansas, South Dakota, North Dakota, Iowa, and Nebraska. The community-based treatment programs include specialty addiction treatment centers representing differently modalities of care; as well as general medical settings of care such as emergency rooms, HIV clinics and family practice centers.  The OVN has participated in over 25 national multi-site clinical trial studies and is one of the most productive CTN nodes in the country.

Grantee Institution: University of Cincinnati

Protocol Involvement

• CTN-0001: Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
• CTN-0002: Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
• CTN-0008: Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating Diffusion of Innovation
• CTN-0012: Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
• CTN-0013: Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome in Pregnant Substance Users
• CTN-0014: Brief Strategic Family Therapy for Adolescent Drug Abusers
• CTN-0015: Women’s Treatment for Trauma and Substance Use Disorders
• CTN-0018: Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
• CTN-0019: Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
• CTN-0028: Osmotic-Release Methylphenidate for ADHD in Adolescents with Substance Use Disorders
• CTN-0029: A Pilot Study of Osmotic-Release Methylphenidate in Initiating and Maintaining Abstinence in Smokers with ADHD
• CTN-0030-A-1: Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
• CTN-0030: Prescription Opiate Abuse Treatment Study (POATS)
• CTN-0031-A-1: An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
• CTN-0031: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
• CTN-0032-A-1: Economic Analysis of HIV Rapid Testing in Drug Abuse Treatment Programs
• CTN-0032: HIV Rapid Testing and Counseling
• CTN-0033-Ot-4: An Exploration of Methamphetamine and Other Drug Use and Treatment Options Among Urban and Rural Northern Plains American Indians
• CTN-0037: Stimulant Reduction Intervention Using Dosed Exercise (STRIDE)
• CTN-0042-S: Efficacy of Motivational Enhancement Therapy for African Americans
• CTN-0044-A-2: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044-A-3: Acceptability of a Web-delivered, Evidence-based, Psychosocial Intervention among Individuals with Substance Use Disorders who Identify as American Indian/Alaska Native
• CTN-0044: Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
• CTN-0046: Smoking Cessation and Stimulant Treatment (S-CAST): Evaluation of the Impact of Concurrent Outpatient Smoking Cessation and Stimulant Treatment on Stimulant Dependence
• CTN-0047-A-1: Site Influences on Treatment Effects – Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments (SMART-ED)
• CTN-0047: Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
• CTN-0048-A-1: Pharmacogenetics of Buprenorphine/Naltrexone for Cocaine Dependence in the CURB Study
• CTN-0048: Cocaine Use Reduction with Buprenorphine (CURB)
• CTN-0049: Project HOPE: Hospital Visit as Opportunity for Prevention and Engagement for HIV-Infected Drug Users
• CTN-0051-A-1: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
• CTN-0051-A-2: Treatment-As-Usual Opioid Use Outcomes Following Discharge from Detoxification and Short-Term Residential Programs Affiliated with CTN-0051
• CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
• CTN-0052: A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC)
• CTN-0053: Achieving Cannabis Cessation — Evaluating N-Acetylcysteine Treatment (ACCENT)
• CTN-0055: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES)
• CTN-0064: Linkage to Hepatitis C Virus (HCV) Care among HIV/HCV Co-infected Substance Users
• CTN-0067: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES): Scale-Up
• CTN-0069-A-1: Retrospective Evaluation of Rapid Buprenorphine Induction in the Emergency Department for Opioid Use Disorder
• CTN-0069: Opioid Use Disorder in the Emergency Department (Project ED Health)
• CTN-0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): A Pragmatic Randomized Trial Comparing Two Buprenorphine Formulations (NIH HEAL Initiative)
• CTN-0093: Validation of a Community Pharmacy-based Prescription Drug Monitoring Program Risk Screening Tool (PHARMSCREEN)
• CTN-0097: Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder
• CTN-0100: Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy
• CTN-0101: Subthreshold Opioid Use Disorder Prevention (STOP) Trial
• CTN-0112: Optimal Policies to Improve Methadone Maintenance Adherence Longterm (OPTIMMAL)
• CTN-0114: Drug Repurposing for Cocaine Use Disorder (CUD) Using a Combined Strategy of Artificial Intelligence (AI)-Based Prediction and Retrospective Clinical Corroboration
• CTN-0125: Integrative Data Analysis of CTN Studies to Examine the Impact of Psychosocial Treatments for Black People who use Cocaine
• CTN-0129: The Great Plains Initiative
• CTN-0131: Office-Based Methadone versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial
• CTN-0134: Buprenorphine-Precipitated Withdrawal Hotspots and Correlates: Identifying Regional “Hotspots” and Potential Correlates of Precipitated Withdrawal During Buprenorphine Induction in Fentanyl Users Through Prescriber Survey Responses and Patient Urine Drug Test Results
• CTN-0138: Adaptation and Implementation of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
• CTN-0142: Towards Personalized Medicine in Medication for Opioid Use Disorder (MOUD): Analyses of Veterans Health Administration Data to Delineate Patient Characteristics Associated with Treatment Outcomes and Successful MOUD Discontinuation